04-Nov-2026 11:39:42
DRREDDY : CLARIFIES NEWS ON $40 HIV PREVENTION SHOT US FDA NOD
• Company confirms First Post headline on US nod for $40 generic HIV prevention shot for 120 poorer countries is correct • News pertains to Nov 2, 2026 press r…
Latest market headlines for DRREDDY on Terminal.
04-Nov-2026 11:39:42
• Company confirms First Post headline on US nod for $40 generic HIV prevention shot for 120 poorer countries is correct • News pertains to Nov 2, 2026 press r…
29-Oct-2026 22:55:26
• Administrative Reg 30 filing of transcript for quarter and half year ended September 30, 2026; no financial figures in the disclosure.
28-Oct-2026 09:33:33
Teriparatide Is To Strengthen Bone Mineral Density
26-Oct-2026 08:45:35
Delivered a strong beat, with adjusted EBITDA of Rs16.4bn, c40% above estimate, & margin improving c580bps QoQ to 19.1%. Ex-Europe, performance was strong acro…
23-Oct-2026 22:37:42
• SEMAGLUTIDE COMMERCIAL RELAUNCH TARGETED FOR NOVEMBER 2026, SUBJECT TO FINAL VALIDATION • FY27 SEMAGLUTIDE VOLUME TARGET MAINTAINED AT 6–7 MILLION DEVICES •…
23-Oct-2026 19:25:11
• NET PROFIT AT ₹913.4 CR VS EST ₹650.8 CR — BEAT BY 40.35% 🟢 • REVENUE AT ₹8,671 CR VS EST ₹8,409 CR — BEAT BY 3.12% 🟢 • EBITDA AT ₹1,783 CR VS EST ₹1,192.6…
23-Oct-2026 18:40:53
Revenue down 1.5% at ₹8,670.8 Cr (YOY), up 7.4% (QOQ). Ebitda down 24% at ₹1,782.8 Cr (YOY); margins 20.6% v 26.7% (YOY), 12.5% (QOQ). Gross margin 52.1% v 54.…
23-Oct-2026 18:13:50
• Global Generics: Revenue down 0.7% YoY to ₹7,790 Cr, up 8% QoQ • North America: Revenue down 23% YoY to ₹2,490 Cr, up 13% QoQ, impacted by lower Lenalidomide…
23-Oct-2026 17:39:11
• REVENUE AT ₹8,697.80 CR VS EST ₹8,805.10 CR — MISS BY 1.22% 🔴 • EBITDA AT ₹1,730.60 CR VS EST ₹1,192.60 CR — BEAT BY 45.11% 🟢 • EBITDA MARGINS AT 19.90% VS…
23-Oct-2026 17:36:11
REVENUE DOWN 1.48% AT ₹8,697.80 CR (YOY), UP 7.38% (QOQ) EBITDA DOWN 13.90% AT ₹1,730.60 CR (YOY), UP 101.26% (QOQ) MARGINS AT 19.90% VS 22.77% (YOY), 10.62% (…
23-Oct-2026 17:32:07
REVENUE UP 7.38% AT ₹8,698 CR (QOQ), DOWN 1.47% (YOY) EBITDA UP 101.28% AT ₹1,731 CR (QOQ), DOWN 13.88% (YOY) MARGINS AT 19.90% VS 10.62% (QOQ), 22.77% (YOY)
23-Oct-2026 17:30:47
License and service income for the quarter ended September 30, 2026 also includes ₹52.9 Cr from sale of US territorial rights relating to Bendamustine HCL. Imp…
21-Oct-2026 09:39:50
• CDSCO under DCGI approved Zytorvi (toripalimab) with cisplatin and paclitaxel for first-line treatment of adults with unresectable advanced, recurrent or met…
07-Oct-2026 14:39:43
• Dr. Reddy's Laboratories Ltd. will announce results for the quarter and six months ended September 30th, 2026 on Friday, October 23rd, 2026, after the Board…
03-Oct-2026 17:17:29
• Dr. Reddy's Laboratories, Inc., a step-down wholly owned subsidiary, received a final transcript from the Department of the Treasury, Internal Revenue Servic…
22-Sept-2026 16:59:24
• Board meeting to be held on Friday, October 23, 2026 • To consider and approve unaudited standalone and consolidated financial results for the quarter ending…
18-Sept-2026 08:47:25
DR. REDDY'S LABORATORIES : EXPANDS COLLABORATION WITH GILEAD SCIENCES FOR HIV PREVENTION DRUG
13-Jun-2026 13:31:50
• Dr. Reddy's announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif®, in the United States. • The company has collab…